Fisher & Paykel Healthcare's total inventories for the quarter that ended in Mar. 2026 was €166 Mil. Fisher & Paykel Healthcare's average total inventories from the quarter that ended in Sep. 2025 to the quarter that ended in Mar. 2026 was €167 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Fisher & Paykel Healthcare's Net-Net Working Capital per share for the quarter that ended in Mar. 2026 was €0.09.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Fisher & Paykel Healthcare's Days Inventory for the
six
months ended in Mar. 2026 was 138.52.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Fisher & Paykel Healthcare's Inventory Turnover for the quarter that ended in Mar. 2026 was 1.32.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Fisher & Paykel Healthcare's Inventory-to-Revenue for the quarter that ended in Mar. 2026 was 0.27.
Fisher & Paykel Healthcare (FRA:FPLB) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
Fisher & Paykel Healthcare's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2026 is
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Fisher & Paykel Healthcare's Inventory to Revenue for the quarter that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
Fisher & Paykel Healthcare Total Inventories Related Terms
Fisher & Paykel Healthcare Total Inventories Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fisher & Paykel Healthcare Total Inventories Chart
Fisher & Paykel Healthcare Total Inventories Calculation
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
Fisher & Paykel Healthcare (FRA:FPLB) has a Total Inventories of €166 Mil as of Mar. 2026. The total amount of inventory as recorded on a company's balance sheet. View historical data for Fisher & Paykel Healthcare and its competitors.
Is Fisher & Paykel Healthcare's Total Inventories too high?
Fisher & Paykel Healthcare's current Total Inventories is €166 Mil. Overall, Fisher & Paykel Healthcare has a GF Score™ of 91/100, reflecting its overall financial health beyond just this single metric.
How does Fisher & Paykel Healthcare's Total Inventories compare to ISRG and BDX?
Fisher & Paykel Healthcare's Total Inventories of €166 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Medical Devices & Instruments company?
A good Total Inventories depends on the Medical Devices & Instruments industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for Fisher & Paykel Healthcare and its competitors. Fisher & Paykel Healthcare's current Total Inventories is €166 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fisher & Paykel Healthcare stock overvalued right now?
Fisher & Paykel Healthcare (FRA:FPLB) has a current Total Inventories of €166 Mil. The stock's GF Value™ is €21.23, compared to a current price of €18.90 — trading 11% below its estimated fair value. The current Total Inventories is €166 Mil. Fisher & Paykel Healthcare's overall GF Score™ is 91/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For Fisher & Paykel Healthcare (FRA:FPLB), the current Total Inventories is €166 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fisher & Paykel Healthcare (FRA:FPLB) Overvalued in 2026?
Based on GuruFocus' analysis, Fisher & Paykel Healthcare stock appears to be undervalued.
The current stock price of €18.90 is trading 11% below its estimated GF Value™ of €21.23.
Key valuation signals for FRA:FPLB:
Total Inventories: €166 Mil
GF Value™: €21.23 vs. price of €18.90 (11% below fair value)
No single metric tells the full story. See the FRA:FPLB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fisher & Paykel Healthcare is one of the three largest respiratory care device companies globally. It is the market leader in hospital use of humidifiers, masks, and related consumables, and the number three player in the at-home treatment of sleep apnea using respiratory devices. Both the hospital and homecare markets for respiratory devices are growing strongly in the developed markets in which Fisher & Paykel has a presence. The company earns roughly half of its revenue in North America, around a quarter in Europe, and approximately a fifth in Asia-Pacific. Fisher conducts its own R&D and has thousands of patents and pending applications. It manufactures in New Zealand, Mexico, and China, and has a multichannel distribution model.
91GF Score
Get the complete analysis for FRA:FPLB
Total Inventories is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:FPLB has been successfully added to your 
